PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.41%
Positive revenue growth while 3088.T is negative. John Neff might see a notable competitive edge here.
9.37%
Positive gross profit growth while 3088.T is negative. John Neff would see a clear operational edge over the competitor.
0.78%
Positive EBIT growth while 3088.T is negative. John Neff might see a substantial edge in operational management.
22.36%
Positive operating income growth while 3088.T is negative. John Neff might view this as a competitive edge in operations.
5.48%
Positive net income growth while 3088.T is negative. John Neff might see a big relative performance advantage.
5.48%
Positive EPS growth while 3088.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
5.48%
Positive diluted EPS growth while 3088.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
23.00%
10Y revenue/share CAGR at 50-75% of 3088.T's 42.88%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
-5.88%
Negative 5Y CAGR while 3088.T stands at 25.28%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-32.18%
Negative 3Y CAGR while 3088.T stands at 19.65%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-100.00%
Negative 10Y OCF/share CAGR while 3088.T stands at 100.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-100.00%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
No Data
No Data available this quarter, please select a different quarter.
38.40%
Net income/share CAGR at 50-75% of 3088.T's 61.37%. Martin Whitman might question if the firm’s product or cost base lags behind.
-5.96%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-29.07%
Negative 3Y CAGR while 3088.T is 26.41%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
90.52%
10Y equity/share CAGR 1.25-1.5x 3088.T's 79.50%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
28.29%
Below 50% of 3088.T's 58.29%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-15.26%
Negative 3Y equity/share growth while 3088.T is at 26.44%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
-41.67%
Cut dividends over 10 years while 3088.T stands at 23965.59%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-50.00%
Negative 5Y dividend/share CAGR while 3088.T stands at 22246.62%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
16.67%
Below 50% of 3088.T's 350.00%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
16779.31%
AR growth well above 3088.T's 1.80%. Michael Burry fears inflated revenue or higher default risk in the near future.
3.78%
We show growth while 3088.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
7.63%
Positive asset growth while 3088.T is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
4.31%
BV/share growth above 1.5x 3088.T's 1.29%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
12.23%
Debt growth of 12.23% while 3088.T is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
-45.53%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.